Nabil Ismaili, Director of Medical Oncology and Radiotherapy Department at Mohammed VI University of Sciences and Health, shared on LinkedIn:
“A Historic Milestone at ESMO 2026: The First Validated mRNA Vaccine in Melanoma.
The Phase 3 INTerpath-001 trial represents a monumental leap forward for adjuvant therapy in high-risk melanoma.
The Trial Design (INTerpath-001):
- Population: Completely resected, high-risk cutaneous melanoma (Stage IIB / IIC / III / IV). N = 1,137.
- Randomization: 2:1, double-blind.
- Experimental Arm: Intismeran autogene (V940 / mRNA-4157) + Pembrolizumab.
- Control Arm: Placebo + Pembrolizumab.
- Primary Endpoint: Recurrence-Free Survival (RFS).
The Results are awaited.
How does this personalized vaccine work? (The Science):
This isn’t an off-the-shelf drug; it is tailor-made for each patient:
- Biopsy/Resection of the tumor.
- DNA Sequencing (Tumor vs. Normal).
- Identification of up to 34 specific neoantigens.
- Formulation of a personalized mRNA vaccine in lipid nanoparticles.
- Vaccination, where the mRNA is taken up by antigen-presenting cells.
- T-cell Priming, expanding neoantigen-specific T cells that recognize and kill residual tumor cells, while forming memory T-cells for long-term protection.
Why this matters:
This is the first validated proof-of-concept that individualized mRNA neoantigen therapy can effectively prevent relapse in a solid tumor.
It opens the door to a new era of highly personalized, precision immunotherapy across multiple cancer types.
Congratulations to the investigators, the patients, and the teams behind this historic trial.
The landscape of adjuvant melanoma treatment is changing before our eyes.
What are your thoughts on the integration of personalized mRNA vaccines into routine oncology practice?
Let’s discuss in the comments!
Proud to be representing UM6SS, Cheikh Khalifa International University Hospital, and Mohammed VI International University Hospital at this incredible moment for science.”
Other articles about cancer vaccines on OncoDaily.
